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Abstract
Objective—There is little information about the combination of genetic variability in pregnant 
women and their children in relation to the risk of preterm delivery (PTD). In a sub-cohort of 487 
non-Hispanic white and 288 African-American mother/child pairs, the Pregnancy Outcomes and 
Community Health Study assessed ten functional polymorphisms in nine genes involved in innate 
immune function.
Methods—Race-stratified weighted logistic regression models were used to calculate odds ratios 
for genotype and PTD/PTD subtypes. Polymorphisms significantly associated with PTD/PTD 
subtypes were tested for mother/child genotype interactions.
Results—Three maternal polymorphisms (IL-1 receptor antagonist intron two repeat (IL-1RN), 
matrix metalloproteinase-9 -C1562T, and TNF receptor two T198G (TNFR2)) and three child 
polymorphisms (IL1-RN, tumor necrosis factor-alpha -G308A, and TNFR2) were associated with 
PTD, but associations varied by PTD subtype and race. Two interactions were detected for 
maternal and child genotype. Among non-Hispanic white women, the odds of PTD was higher 
when both mother and child carried the IL-1RN allele two (additive interaction p<.05). Among 
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African-American women, the odds of PTD was higher when both mother and child carried the 
TNFR2 G allele (multiplicative interaction p<.05).
Conclusion—These results highlight the importance of assessing both maternal and child 
genotype in relation to PTD risk.
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premature birth; inflammation; maternal & child genotype; gene-gene interactions; genetic 
polymorphisms; premature birth genetics
Introduction
Preterm delivery (PTD) is a leading cause of infant mortality and a major contributor to 
child neurodevelopmental problems. The U.S. PTD rate has risen 30% since 1981 with 
12.7% of all pregnancies in 2005 delivered preterm [1]. The causes of PTD are not fully 
understood but multiple, complex, and sometimes overlapping pathways appear to be 
involved. Several findings suggest that inflammatory processes contribute to the etiology of 
PTD. For example, high levels of pro-inflammatory cytokines collected in mid-pregnancy 
maternal serum, mid-pregnancy amniotic fluid, and mid-pregnancy cervical samples have 
been associated with an increased risk of spontaneous PTD; although these findings have not 
been consistent across all studies [2-4]. Activation of inflammatory pathways and cytokine 
production can induce prostaglandin synthesis and production of collagenases. In turn these 
substances may initiate uterine contractions and remodeling of the collagen in the cervix and 
gestational membranes which ultimately culminates in preterm labor and/or preterm rupture 
of membranes [5].
Variability in the genome of pregnant women affects susceptibility to exogenous and 
endogenous factors and these interactions might trigger pathways culminating in PTD. For 
example, one study reported that maternal genomic variations influence inteleukin-1β 
response to anaerobic Gram-negative bacteria and Gardnerella vaginalis in the vagina and 
the risk of spontaneous PTD [6]. Variability in fetal genome also influences local immune 
responses to environmental factors that may alter the risk of PTD and sequelae of 
prematurity [7]. Findings from twins studies estimate the heritability of PTD to be about 
one-third [8], with data from large epidemiologic studies suggesting that maternal genotype 
contributes more substantially than paternal genotype to the risk of PTD [9]. Although the 
effect of maternal or child genotype has frequently been analyzed in separate studies, it has 
less often been analyzed in the same study, and rarely have interactions between maternal 
and child genotype been tested. Most recently the identification of a maternal/child genotype 
interaction in a large case-control study of over 700 polymorphisms lends support to the 
hypothesis that maternal and fetal genotype may interact to increase the risk of PTD [10].
In the Pregnancy Outcomes and Community Health (POUCH) Study, we studied ten genetic 
polymorphisms in mothers and their children. The polymorphisms were selected on the basis 
of published associations with PTD [11-15] and associations with variation in the extent of 
inflammation processes (see Table II) [7,12,16-21]. We choose to analyze polymorphisms in 
candidate genes rather than explore genome-wide associations. The candidate gene approach 
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has the advantage of maximizing inferences about biologic plausibility and disease causality 
when previous information exists about the function of the gene in disease processes, 
however, this approach is not ideal for initial gene discovery. One of our main objectives 
was to evaluate the interaction between maternal and child genomic variations in relation to 
the risk of PTD using the candidate gene approach.
Methods
Study Population and Data Collection
The POUCH Study enrolled a cohort (n=3,038) of pregnant women at 15-27 weeks 
gestation from 52 participating clinics in five Michigan communities from 1998 through 
2004. The study was designed to assess biologic and psychosocial risk factors for PTD. 
Detailed methods have been given elsewhere [22]. Women were sampled at the time of 
prenatal maternal serum alpha-fetoprotein (MSAFP) screening (15-22 weeks). Women with 
unexplained high MSAFP (i.e. > 2 multiples of the median in singletons with no birth 
defect) were over-sampled (7% of cohort) due to a special interest in this biomarker in 
relation to PTD. Exclusion criteria included known fetal anomalies, preexisting diabetes, 
multi-fetal gestations, and non-English speaking. POUCH Study participants were found to 
be comparable on most maternal characteristics when compared to women delivering in the 
respective communities. At enrollment, participants provided biologic samples and 
completed both a self-recorded questionnaire and an in-person interview that included 
demographic data. A woman who indicated that she belonged to more than one racial group 
was asked to select the one that best described her racial identity. In this analysis, the child 
was considered to be of the same race as the mother. Analyses presented here were 
conducted in a sub-cohort (n=1371) that was sampled for in-depth investigations. The sub-
cohort was randomly sampled at enrollment based on a stratum-specific sampling 
probability (varied by race/ethnicity and MSAFP level). At delivery the final sub-cohort was 
defined and included all pre-sampled cohort women and all cases of PTD. The final sub-
cohort included all women who delivered preterm, those with unexplained high MSAFP, 
and a race-stratified random sample of women who delivered at term and had normal 
MSAFP. The clinical data were obtained in the sub-cohort through medical chart review by 
study nurses and physicians.
Definition of preterm delivery
Gestational age at delivery was estimated by using the date of last menstrual period (LMP). 
Dating was based on the earliest ultrasound if the ultrasound-based estimate differed from 
the LMP-derived estimate by more than two weeks. PTD was defined as delivery before the 
37th week of gestation. In some analyses, the results were stratified according to the clinical 
circumstances of the PTD. Delivery that occurred by Cesarean section or induction without 
prior spontaneous labor or rupture of membranes were grouped into medically indicated 
(MI) births. PTD cases in which the onset of labor or rupture of membranes occurred as the 
initiating event were considered spontaneous (SPT).
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Between 2005 and 2007, DNA was collected from children born to women in the POUCH 
Study subcohort. Women whose fetus/child had died (n= 19), those who had declined to 
participate in any future studies at enrollment in the cohort (n=69), or who were deceased 
(n=3) could not be included in this follow-up study. Attempts to contact the remaining sub-
cohort women (n=1280) were made via mail and telephone. During the study follow-up 
period 1,024 sub-cohort women were located and 1,006 were contacted. Ten women were 
no longer living with their child and were not able to give consent for their child to 
participate. Forty-one mothers who were contacted during the follow-up period declined to 
participate in the child DNA collection. Child DNA collection kits were mailed to 955 
consenting women and 865 kits were returned (68% of the 1280 eligible). The collection kit 
contained ten sterile cotton swabs to collect buccal cells from inside the child's mouth. The 
swabs were placed into a tube containing a sodium dodecyl sulfate-based buffer and shipped 
overnight back to the study [12]. Fifty mother/child pairs belonged to race/ethnic groups 
other than non-Hispanic white and African American. This number was too small for a 
meaningful analysis and therefore these pairs were excluded. In 36 mothers DNA was 
unavailable or unsuitable for testing. In 4 mother/child pairs genotypes that were 
incompatible with maternity were found across multiple assays (homozygous rare genotype 
with homozygous common genotype pairings) suggesting an error in sample collection or 
handling. These samples were excluded from analyses leaving 775 mother/child pairs for 
final analysis.
DNA Extraction and Genotyping
Maternal genomic DNA was extracted from venous samples collected at enrollment using 
the Gentra Systems (Minneapolis, MN) Puregene™ kit. DNA of the children was extracted 
using a phenol/chloroform method from buccal swabs (Puritan Cotton Tipped Applicators 
REF 803-PC) collected by their mothers [23].
For maternal TNF-α and IL-1β polymorphisms, genotyping was performed using TaqMan® 
Assays-on-Demand™, which consist of polymerase chain reaction (PCR) primers and a 
fluorescently-labeled probe (Applied Biosystems, Foster City, CA). Two primer/probe sets 
were used that were specific to SNPs in IL-1β or TNF-α. End-point fluorescent detection 
was performed on an ABI Prism® 7900HT Sequence Detection System. Genotypes were 
evaluated using SDS software (v.2.1). Duplicate analyses were performed on a randomly 
selected sample representing ≥ 15% of the individuals and a reproducibility rate of 99.9% 
was observed.
The remaining eight maternal and all child polymorphisms were genotyped using PCR and 
primer pairs that spanned the polymorphic regions followed by restriction enzyme digestion 
and agarose gel electrophoresis according to previously published protocols: rs# 73271540 
in CD14 [11], rs# 4986790 in toll-like receptor-4 (TLR-4) [16], a variable number of tandem 
repeats in intron 2 of interleukin-1 receptor antagonist (IL-1RN) [13], rs# 1143634 in 
interleukin-1 beta (IL-1β) [13], rs# 1800629 in tumor necrosis factor alpha (TNF-α) [24], rs# 
72863489 in tumor necrosis factor receptor 2 (TNFR2) [25], rs# 978522 in Fas (TNFSR6) 
[26], rs# 73622645 in matrix metalloproteinase 9 (MMP-9) [27], rs# 1800450 and rs# 
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1800451 in mannose binding lectin (MBL) [28,29]. Incompatible maternal/child genotype 
combinations were found for 39 polymorphism assay results. These discordant results were 
not clustered within any single mother/child pair, therefore we assumed the errors occurred 
within each assay process; 39 errors with 15,500 assays is equivalent to an error rate of 
2.5%. We excluded these inconsistent mother/child results from individual analyses but did 
not exclude the mother/child pair from the entire dataset.
Statistical Analysis
The analytic plan involved evaluation of the ten candidate polymorphisms in relation to risk 
of PTD using race-specific models, first considering maternal genotypes and then 
considering child genotypes. To reduce type I errors we did not consider all possible mother/
child gene interactions. We focused on positive polymorphisms from the aforementioned 
analyses and considered potential maternal and child genotype interaction within a single 
gene. All models were stratified on race to rule out potential effects due to population 
stratification and because of the higher rate of inflammation/infection-related PTD among 
African Americans compared to that in non-Hispanic whites [30].
For descriptive purposes, Chi-square statistics were used to: 1) compare maternal 
characteristics in POUCH Study mothers who participated in the child DNA collection to 
maternal characteristics in the entire POUCH Study sub-cohort; 2) test for Hardy Weinberg 
equilibrium among each polymorphism in race-stratified groups of women who delivered at 
term with normal MSAFP; and 3) compare the race-specific allele frequencies among 
women who participated in the child DNA collection and women who did not have a child 
DNA sample.
Genotypes were divided into two classes with the homozygous common allele genotype as 
the reference group and the heterozygotes and the homozygous rare-allele genotypes 
grouped as the ‘risk’ group, also known as the dominant model. This strategy was chosen to 
maximize statistical power and to limit the number of comparisons. IL1-RN had more than 
two allelic forms, but alleles three, four, and five were very rare and were excluded (n=18). 
Based on previously published data, allele two was treated as the ‘risk’ allele and the allele 
one homozygotes were used as the reference group [6].
We applied weighted logistic regression (SAS Version 9.1.3 Proc Surveylogistic) to 
examine potential differences in the odds of PTD associated with maternal and child 
genotypes and their interactions. All regression analyses incorporated sampling weights 
accounting for oversampling of high MSAFP, African-American women, and PTD.
In weighted logistic regression, we considered maternal genotypes first and then child 
genotypes. Both maternal and child genotypes were then considered for potential genotype 
interaction within a single gene. The effect of genotype interaction on PTD risk was tested 
for the four genetic polymorphisms that had significant maternal or child genotype main 
effects on PTD: IL1-RN (non-Hispanic white), IL-1β (African American) MMP-9 (non-
Hispanic white), TNF-α (African American) and TNFR2 (African American). The 
significance of interactions was tested on the multiplicative (p-value for the interaction term 
from logistic regression) and additive scales (relative excess risk due to interaction) [31].
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The response categories in the weighted logistic regression were first binary (i.e. Term or 
PTD) and then polytomous (i.e. Term (Ref), MI PTD, or SPT PTD). The modeling of 
clinical subtypes of PTD was planned a priori because distributions of causal pathways 
differ across these subtypes. However, in the analyses of the maternal child genotype 
combinations we used only the binary outcome due to limited power.
Analyses were repeated using Cox proportional hazards models adapted to the case-cohort 
design (Proc PHREG) to calculate hazard ratios and confidence intervals with standard 
errors based on the robust sandwich estimate [32]. The risk estimates and odds ratios 
obtained from logistic models and the proportional hazard models were similar and the 
findings related to the combinations of maternal and child genotype did not change. Here we 
present results from the logistic models only.
Results
There were 487 non-Hispanic white (n=131 PTD) and 288 African-American (n=49 PTD) 
maternal child pairs in this sample (Table I). The majority of non-Hispanic whites (66%) 
and a minority of African-American women (36%) had greater than a high school education. 
For both African Americans and non-Hispanic whites ∼40% of women were primiparous. 
The PTD rate was 10% in non-Hispanic white women, and 14%, in African-American 
women. In race stratified comparisons, characteristics (maternal age, maternal education, 
Medicaid Insurance use, parity, and PTD rates) of women whose children had genetic 
analysis did not differ significantly (p >.05) from those in the entire POUCH Study sub-
cohort (data not shown).
The MMP-9 polymorphism in the non-Hispanic white women was the only genotype that 
deviated from Hardy-Weinberg equilibrium. Race-specific polymorphism frequencies 
among women who delivered at term and preterm are presented in Table II. Maternal allele 
frequencies did not differ between the sample with child DNA (participants in the follow-up 
collection) and the sample without child DNA (non-participants in the follow-up collection) 
(data not shown).
Results from analysis of maternal polymorphisms in relation to PTD are presented in Table 
III. In non-Hispanic white women significant findings included the IL1-RN allele 2 length 
polymorphism and increased odds of PTD, and polymorphisms in the IL1-RN gene and the 
MMP-9 gene and increased odds of SPT PTD. Among African-Americans the TNFR2 G 
allele was associated with increased odds of SPT PTD. In both racial groups none of the 
maternal polymorphisms were significantly associated with only MI PTD.
Results for the child polymorphisms are presented in Table IV. In non-Hispanic whites 
statistically significant findings included the IL1-RN allele 2 length polymorphism and 
increased odds of both PTD and SPT PTD and an inverse association between TNFR2 allele 
G and odds of MI PTD. A statistically significant inverse relation was found for TNF-α 
allele A and PTD in African Americans.
Maternal and child polymorphism interactions are presented in Table V. Among non-
Hispanic white mother/child pairs, the odds of PTD was significantly increased when both 
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mother and child had the IL1-RN 2 allele (odds ratio = 2.3; 95% confidence interval 1.3, 3.8, 
significant additive interaction), but not when this variant allele was present only in the 
mother or child. Among African-American mother/child pairs, the odds of PTD was 
increased when both mother and child carried the TNFR2 G allele (odds ratio 1.6; 95% 
confidence interval 0.8, 3.4, significant multiplicative interaction) but not when this allele 
was present only in the mother or child.
Discussion
We studied ten polymorphisms in nine genes regulating innate immunity in the mother and 
her child. Eight of the ten polymorphism have been linked to PTD in reports of maternal 
genotype, but these associations have been inconsistent [12,14,15,33-35]. Several of our 
findings paralleled results from previous studies. We were able to replicate associations 
between SPT PTD and both maternal and child IL1-RN allele 2 length polymorphism in the 
non-Hispanic whites [13,36]. The TNF-α A allele was protective for PTD among African-
American children [37]. In addition, we identified two new positive associations between 
spontaneous PTD and a maternal polymorphism, one with MMP-9 in the non-Hispanic 
whites and the other with TNFR2 in African-Americans. We also showed that maternal IL1-
RN allele 2 confers a risk of PTD in the non-Hispanic white mothers only if her child also 
inherits this allele. The same phenomenon was observed for the TNFR2 polymorphism in 
African-Americans
In the initial design of our study, we hypothesized that the effects of polymorphisms might 
differ for SPT PTD versus MI PTD, though inflammatory responses could be relevant to 
both. Most prior genetic studies of preterm birth have excluded MI PTD. Our statistically 
significant findings were found primarily in relation to SPT PTD, however, in many 
analyses the number of MI PTD in a given stratum were too few to allow firm conclusions. 
Larger studies will be needed to explore genetic risk factors across clinical subsets of PTD.
Based on birth certificate data, the POUCH Study cohort participants were representative of 
the communities from which they were sampled. Although only 68% of the eligible sub-
cohort women participated in this follow up study, there were no differences in maternal 
demographic characteristics or allelic frequencies between women whose children were 
included in the genetic analysis and women in the entire sub-cohort. Only 1% (19) of the 
children were deceased at the time of DNA collection. It is therefore unlikely that significant 
bias was introduced due to sampling or genetic characteristics associated with survival.
This and other studies demonstrate that the inflammation- related polymorphisms associated 
with PTD may differ across s race/ethnicity groups. These variations suggest the importance 
of gene-gene and gene-environment interactions in inflammatory pathway affecting PTD 
risk. Genetic association studies focusing on PTD should therefore account for ethnic 
variation. In this study we stratified our study population according to race/ethnicity self-
reported by the mother. In our data, most maternal allele frequencies were significantly 
different by race. Paternal race was reported to be the same as the mother's in 96% of non-
Hispanic-white women and in 89% of African-American women. We relied on mother's 
report to define her and her partner's race and did not identify ancestry informative markers 
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that are often used to reduce bias due to population stratification. At least one study suggests 
that this the bias may be minimal in US Caucasian populations [38].
The statistically significant associations between PTD and genetic variation observed in this 
study would have been lost had we corrected for multiple comparisons. It is therefore 
possible that some of the associations reported here may be spurious. It is, however, notable 
that the association with SPT PTD and ILRN has been independently confirmed by other 
studies [12]. Our findings related to MMP-9 1562 and TNFR2 198 polymorphisms are novel 
and await future confirmation.
This study was adequately powered (β=80%) to detect an odds ratio of 2.0 associated with 
an adverse outcome and presence of a minor allele with a prevalence of 15%. However, it 
lacked the power to analyze interactions between multiple genetic markers and haplotypes. 
We also lacked statistical power to subdivide PTD further by gestational weeks. Therefore 
associations tightly linked to gestational age-related PTD phenotypes may have been 
missed. It is also possible that we failed to identify associations for the more rare variants. 
Notably we had limited power to test for interactions for some gene-gene combinations and 
therefore our negative findings could be the result of type II error.
Replication is an important part of the process to understand the strength and consistency of 
relations among specific genes and PTD across a variety of methodologic approaches. As 
part of this process, both positive and negative findings are informative. To date, genetic 
studies of PTD have struggled with reproducibility. Differences across study populations in 
genetic background and environmental exposures may be important contributors to the 
inconsistent results. Our study approached the question by trying to replicate findings from 
previous studies, by selecting candidate functional polymorphisms and by specifically 
examining maternal and child genotype combinations. In a recent review, the challenges of 
non-replication in gene association studies are highlighted and include issues of 
polymorphism selection, bias due to population stratification, low power, and reporting bias 
[39].
A recent large-scale candidate gene study in a Chilean population included polymorphisms 
in both maternal and child DNA and used several different analytic techniques (i.e. single 
locus tests, haplotype tests, multi-locus analysis, pathway analysis) to explore genetic 
associations in relation to PTD [10]. Across multiple analytic techniques, their findings were 
consistent with the hypothesis that genetic variations along the inflammation pathway in 
both mother and fetus are important risk factors for PTD. In addition, they identified a 
significant three-way interaction between a maternal polymorphism (collagen type IV alpha 
4) and two fetal polymorphisms (collagen type IV alpha 4 and fibroblast growth factor 1). 
The importance of the specific polymorphisms identified by their work may not be directly 
comparable to the findings in our study due to differences in ethnicity and environmental 
exposures across our study populations.
Our findings, although preliminary, in combination with others suggest that genetic models 
examining the risk of PTD should consider interactions between maternal and child 
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genotypes. These models will be potentially more illuminating when gene-environment 
interactions are also incorporated.
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Table III
Maternal gene polymorphisms and preterm delivery
Preterm Subtype
Preterm Overall Medically Indicated Spontaneous
Gene Ethnicity OR (95% CI) OR (95% CI) OR (95% CI)
CD14 -C159T (rs# 73271540) Non-Hispanic white 0.9 (0.5, 1.4) 0.9 (0.4, 1.9) 0.9 (0.5, 1.5)
African American 1.5 (0.8, 3.0) 2.0 (0.5, 8.4) 1.4 (0.6, 3.0)
IL-1β C3954T (rs# 1143634) Non-Hispanic white 1.0 (0.6, 1.5) 0.7 (0.3, 1.4) 1.2 (0.7, 1.9)
African American 0.6 (0.2, 1.3) NE 0.8 (0.3, 1.9)
IL-1RN allele 2, Intron 2 repeats Non-Hispanic white 1.9 (1.2, 2.9)* 1.6 (0.8, 3.2) 2.0 (1.2, 3.3)*
African American 0.4 (0.1, 1.3) 0.8 (0.2, 4.1) 0.3 (0.1, 1.4)
MBL G54A (rs# 1800450) Non-Hispanic white 1.3 (0.8, 2.2) 0.8 (0.3, 2.0) 1.5 (0.9, 2.7)
African American 1.3 (0.4, 3.8) NE 1.8 (0.6, 5.2)
MBL G57A (rs# 1800451) Non-Hispanic white 1.3 (0.6, 3.0) 1.6 (0.4, 5.6) 1.3 (0.5, 3.2)
African American 1.2 (0.6, 2.2) 1.1 (0.3, 4.0) 1.2 (0.6, 2.4)
MMP-9 -C1562T (rs# 73622645) Non-Hispanic white 1.5 (0.9, 2.3) 1.1 (0.5, 2.3) 1.7 (1.0, 2.8)*
African American 1.2 (0.6, 2.5) 1.1 (0.3, 4.5) 1.2 (0.5, 2.8)
TLR4 A896G (rs# 4986790) Non-Hispanic white 1.4 (0.8, 2.7) 1.9 (0.7, 5.0) 1.3 (0.6, 2.6)
African American 0.4 (0.1, 1.8) 0.9 (0.1, 7.5) 0.3 (0.0, 2.0)
TNF-α -G308A (rs# 1800629) Non-Hispanic white 0.9 (0.6, 1.4) 1.2 (0.6, 2.6) 0.8 (0.4, 1.3)
African American 0.4 (0.2, 1.0) 0.5 (0.1, 2.6) 0.4 (0.1, 1.1)
TNFR2 T198G (rs# 72863489) Non-Hispanic white 1.1 (0.7, 1.7) 0.7 (0.3, 1.4) 1.3 (0.8, 2.1)
African American 1.6 (0.9, 3.1) 0.4 (0.1, 2.1) 2.3 (1.1, 4.6)*
TNFRSF6 -A670G (rs# 978522) Non-Hispanic white 0.7 (0.4, 1.1) 0.8 (0.4, 1.6) 0.7 (0.4, 1.1)
African American 0.7 (0.2, 2.3) NE 0.5 (0.2, 1.8)
CI = Confidence Interval, NE = Not Estimable, OR= Odds Ratio
*
p<.05
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Table IV
Child gene polymorphisms and preterm delivery
Preterm Subtype
Preterm Overall Medically Indicated Spontaneous
Gene Ethnicity OR (95% CI) OR (95% CI) OR (95% CI)
CD14 -C159T (rs# 73271540) Non-Hispanic white 0.8 (0.5, 1.2) 0.9 (0.4, 1.8) 0.7 (0.4, 1.2)
African American 1.0 (0.5, 2.0) 0.8 (0.2, 2.7) 1.1 (0.5, 2.3)
IL-1β C3954T (rs# 1143634) Non-Hispanic white 1.0 (0.6, 1.5) 0.8 (0.4, 1.6) 1.1 (0.7, 1.8)
African American 1.2 (0.6, 2.5) 0.2 (0.0, 1.5) 1.7 (0.7, 3.6)
IL-1RN allele 2, Intron 2 repeats Non-Hispanic white 1.6 (1.1, 2.5)* 1.5 (0.7, 3.0) 1.7 (1.0, 2.8)*
African American 1.2 (0.6, 2.7) 1.8 (0.4, 7.4) 1.1 (0.4, 2.7)
MBL G54A (rs# 1800450) Non-Hispanic white 1.0 (0.6, 1.6) 1.3 (0.6, 2.9) 0.8 (0.5, 1.5)
African American 1.1 (0.3, 3.5) NE 1.5 (0.4, 4.9)
MBL G57A (rs# 1800451) Non-Hispanic white 1.1 (0.5, 2.3) 1.2 (0.3, 4.2) 1.0 (0.4, 2.5)
African American 1.5 (0.8, 2.9) 1.5 (0.4, 5.1) 1.5 (0.7, 3.2)
MMP-9 -C1562T (rs# 73622645) Non-Hispanic white 0.9 (0.6, 1.5) 0.8 (0.3, 1.8) 1.0 (0.6, 1.7)
African American 1.0 (0.5, 2.1) 3.0 (0.9, 11.0) 0.7 (0.3, 1.6)
TLR4 A896G (rs# 4986790) Non-Hispanic white 1.4 (0.8, 2.5) 1.2 (0.4, 3.3) 1.5 (0.8, 2.8)
African American 0.5 (0.2, 1.4) 1.1 (0.2, 5.5) 0.3 (0.1, 1.3)
TNF-α -G308Am (rs# 1800629) Non-Hispanic white 0.7 (0.5, 1.2) 0.5 (0.2, 1.2) 0.8 (0.5, 1.4)
African American 0.4 (0.2, 1.0)* 0.5 (0.1, 2.4) 0.4 (0.2, 1.1)
TNFR2 T198G (rs# 72863489) Non-Hispanic white 1.1 (0.7, 1.6) 0.3 (0.1, 0.7)* 1.6 (1.0, 2.2)
African American 1.0 (0.5, 1.9) 0.2 (<.1, 1.8) 1.3 (0.6, 2.7)
TNFRSF6 -A670G (rs# 978522) Non-Hispanic white 1.0 (0.6, 1.6) 1.0 (0.5, 2.2) 1.0 (0.6, 1.7)
African American 0.7 (0.2, 1.7) 0.4 (0.1, 2.2) 0.8 (0.2, 2.4)
CI = Confidence Interval, NE = Not Estimable, OR = Odds Ratio
*
p<.05


































































































































































































































































































































































































































































































































































































































































J Matern Fetal Neonatal Med. Author manuscript; available in PMC 2015 November 12.
